Bolt Biotherapeutics vs HCW Biologics
BOLT and HCWB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BOLT and HCWB compare
Bolt Biotherapeutics is the larger company, worth 7.7 times as much as HCW Biologics ($11.4M against $1.5M).
HCW Biologics grew revenue faster over the last twelve months (700% versus 12.8% for Bolt Biotherapeutics).
HCW Biologics keeps more of each dollar of sales as profit, with a net margin of −83.8% compared with −611% at Bolt Biotherapeutics.
Bolt Biotherapeutics scores higher on the StockData Score (11 against 6 for HCW Biologics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BOLT | HCWB |
|---|---|---|
| Size and price | ||
| Market cap | $11.4M | $1.5M |
| Share price | $5.91 | $0.801 |
| Change, 1 year | 22.9% | −95.3% |
| Change, 5 years | −96.6% | −99.9% |
| Beta (5Y) | 0.61 | 0.73 |
| Employees | 23 | – |
| StockData Score | ||
| Total score | 11 (better) | 6 |
| Valuation score | 3 | 3 |
| Growth score | 2 | 2 |
| Performance score | 1 | 1 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.4× | 0.2× (better) |
| P/B | 0.9× | 0.2× (better) |
| Fair value | $8.92 | $14.89 |
| Margin of safety | 33.7% | 94.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 12.8% | 700% (better) |
| Revenue growth, 5Y average | 102% (better) | −57.9% |
| Profitability | ||
| Gross margin | – | 96.7% |
| Operating margin | −655% | −115% (better) |
| Net margin | −611% | −83.8% (better) |
| Return on equity | −112% (better) | −151% |
| Return on invested capital | – | −70.7% |
| Financial health | ||
| Debt / equity | 0.00 | 0.88 (better) |
| Interest coverage | – | −14.0× |
| Current ratio | 2.61 (better) | 0.06 |
| Altman Z-score | −18.28 | −7.20 (better) |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −0.26% | – |
| Shareholder yield | −0.26% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 31.0% | 5.6% |
| Held by insiders | 12.2% | 34.9% |
| Insider net buying, 12 months | $196K | $532K (better) |
| Short interest, % of float | 2.8% | 4.1% |
Go deeper
- BOLT stock overview
- BOLT income statement
- BOLT valuation and score
- HCWB stock overview
- HCWB income statement
- HCWB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.